Insync is fully invested globally

From

Monik Kotecha questions the attitude of some international managers who are holding high cash holdings. Monik’s Insync Funds have registered top quartile performance while being fully invested (residual cash position

continue reading

Insync keeps its booking.com investment – travel will return

From

Insync Funds Management defies the gloom around COVID-19 and travel/tourism by retaining its holding in booking.com. “Insync believes that bookings.com (as a major player) will get a huge share of

continue reading

Megatrends possess an aura of inevitability for Insync

From

Over the next 15 years we will experience more change than ever in human history. Simply investing along country and sector lines will no longer provide the potential differentiation or

continue reading

Insync Funds Management appoints Portfolio Manager to the Global Titans Fund

From

Insync Funds Management is pleased to announce the appointment of John Lobb as portfolio manager within the investment team. John has over 25 years of analytical and portfolio management experience.

continue reading

The downgrading of global growth by the IMF is not hurting all businesses

From

“The slowdown in the global economy will have relatively minimal impact on the outlook for Medtronics which is benefitting from the powerful megatrend in the growing demand for healthcare products

continue reading

Nestlé: from chocolates, soft drinks to now marketing wellness and therapy

From

“As the world’s largest food + beverage company, Nestlé, is now focusing on nutritional therapy, a diversification effort that taps into the fast-growing, high-margin healthcare product market,” said Mr Monik

continue reading

Fund manager sees continuing growth from rising African consumer markets juggernaut

From

Insync Funds Management is predicting that Africa will be the next big growth region for stock pickers. The fund manager’s Chief Investment Officer, Monik Kotecha, said that investors will soon

continue reading

Global Biotechnology identified as a megatrend

From

Insync Global Titans Fund has invested in global biotechnology company Thermo Fisher Scientific on an attractive free cash flow yield of 5.7 per cent for 2016. Ageing populations, the need

continue reading

Insync continues to increase the fund’s exposure to global healthcare

From

“The slowdown in China will have relatively minimal impact on the outlook for Medtronics which is benefitting from the powerful megatrend in the growing demand for healthcare products and services

continue reading

The Insync Global Titans Fund added to Macquarie Wrap

From

Insync’s international equities fund, Insync Global Titans Fund, has been added to the investment and superannuation/pension menus of Macquarie Wrap. “We are very pleased to be added onto the Macquarie

continue reading